

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

General Management Issues

TITLE: *Bio-orthogonal catalysis for cancer therapy*

ACRONYM: *THERACAT*

DURATION: *01/03/2018 – 28/02/2022 (4 years project)*

PROJECT ID: *765497*

FUNDED UNDER: *H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers*

TOPIC: *MSCA-ITN-2017 - Innovative Training Networks*

FUNDING SCHEME: *MSCA-ITN-ETN - European Training Networks*

USEFUL WEBSITES:

- CORDIS Web: <https://cordis.europa.eu/project/rcn/215989/factsheet/en>
- THERCAT Web: www.theracat.eu/
- THERACAT Intranet: <https://theracat.eu/wp-login.php>

CONFIDENTIAL FILES

RELEVANT DOCUMENTS (Available on the intranet):

- *GRANT AGREEMENT (GA, Declaration of Honour, Data sheet)*
- *CONSORTIUM AGREEMENT*

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

Boards

SUPERVISORY BOARD:

- Will be the ultimate **decision-making body** of the project (**majority vote**), being responsible for implementing the project strategy, both from the scientific and training perspectives, within the budget and time frame of the project, always maintaining research integrity according to the "[European Code of Conduct for Research Integrity](#)".
- It will be composed by the Coordinator and one representative from each beneficiary:
 - IBEC: Dr. Albertazzi (Chair).
 - TU/e: Dr. Palmans.
 - GRO: Dr. Roelfes.
 - BAS: Dr. Ward.
 - EDI: Dr. Unciti-Broceta.
 - TAU: Dr. Satchi-Fainaro.
 - TEVA: Dr. Avramovitch.
 - TAG: Dr. Robillard.
 - BGX: Dr. Goldie.

One representative from the recruited ESRs will also be part of the SB and attend the future meetings.

SUPERVISORY BOARD:

- This board will be responsible for:
 - ensuring **recruitment procedures** are open, transparent, and internationally comparable.
 - **overseeing the integration** of the fellows in the hosting institution and their mentoring.
 - ensuring that **scientific and technological training** through personalised research projects is balanced with **complementary skills training** to guarantee future ESR employability in all sectors.
 - monitoring the **implementation** of the research and training plan and solving any problem that may arise.
 - guaranteeing the **exchange of best practices** among partners.
 - providing uniform procedures to the Network through the elaboration and **approval of guidelines** for the elaboration of the PCDPs, the recruitment and assessment of ESRs, and the Strategy for dealing with scientific misconduct.

Supervisory Board Meetings: once a year (coinciding with Network Meetings)

RECRUITMENT COMMITTEE:

- It is responsible for advertising vacancies within the ETN, as well as implementing the Recruitment Strategy.
- It will be chaired by the coordinator (IBEC) and formed by:
 - Prof. Prats (UAB)
 - Prof. Ward (BAS)
 - Prof. Palmans (TU/e)

At practical level: Consultant Board in case of conflicts (having on mind that each beneficiary is the main responsible of the recruitment process).

- This committee will be responsible for (IBEC has supervised all the actions):
 - developing a recruitment plan defining the step by step process of employment.
Done (Recruitment Plan sent to all partners)
 - ensuring gender balance within the recruitment.
Done (53% female ESRs)
 - Advertising positions internationally.
Done (all positions advertised in EURAXESS & other international webpages)
 - dealing with any problem that may arise in the recruitment process.
Done (support provided to all partners whenever needed)

RECRUITMENT COMMITTEE:

- Recruitment Plan for H2020-ITN THERACAT (Document prepared by IBEC) – MS1

1. The Recruitment Committee	3
1.1 Recruitment Committee Members	3
2. Eligibility Criteria.....	4
3. Recruitment Procedure	5
3.1 Job Description	5
Defining the advertised roles.....	5
Equal Opportunities.....	5
Other obligations towards recruited researchers	5
Job Description Template	5
3.2 Advertising the Positions.....	6
3.3. Candidate Selection.....	6
Selection Panel	6
Interview Selection Format.....	6
References	6
3.3 Successful Candidates	6
Researcher declaration.....	6
Employment contract.....	7
“Domestic Issues”	7
ANNEX 1. Job Description (Template)	8
ANNEX 2. Interview Assessment (Template).....	12
ANNEX 3. Minutes of the selection process (Template)	14

TRAINING COMMITTEE:

- Will be responsible for implementation of the Network based **training activities** and will care about the organisation of the Network wide training activities, the intermediation in training related **conflicts, advising appropriate training directions**, and in the follow up of Doctoral Studies (**At practical level: Consultant Board in case of conflicts**).
- It will be chaired by Dr. Amir (TAU) and formed by:
 - Dr. Albertazzi (IBEC)
 - Dr. Goldie (BGX)
 - Prof. Roefles (GRO)

Providing academic and industrial experience.
- . This committee will be responsible for:
 - defining the Network training activities.
 - evaluating the integration of the Network into local training programmes.
 - supervising and managing all the training activities,
 - supporting the definition of the Personal Career Development Plan (PCDP) for each ESR under the guidance of their supervisors outlining the individual learning objectives and skills to acquire throughout their doctoral/research training for their career development.

IP & INNOVATION COMMITTEE:

- It is the body responsible for advising on **Intellectual Property and Innovation activities** related to the research developed within the project, with the support of the Tech Transfer departments of the members' institutions (**At practical level: Consultant Board in case of conflicts**)
- It will be chaired by Dr. Avramovitch (TEVA) and formed by:
 - Dr. Robillard (TAG)
 - Dr. Unciti Broceta (EDI)
 - Prof. Satchi-Fainaro (TAU)

Providing academic and industrial experience.

- This committee will be responsible for:
 - periodic monitoring of the project scientific results, assessing the scientific achievements and progress.
 - determining whether some results are patentable.
 - investigating competitive landscapes and potential exploitation issues.

FELLOWS COMMITTEE:

- Will represent all the research fellows and will be led by 3 ESRs each year, selected yearly by all ESRs by majority vote.
- Within this board ESRs will:
 - discuss the network strategies and transfer to other relevant Committees when needed;
 - launch fellow-related initiatives;
 - supply inputs for the improvement of the programme (e.g. new training activities);
 - among others.

Will be formed next Friday March 29th.

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

Recruitment

RECRUITMENT PROCESS:

- ESRs selected: 13/13
- ESRs already working: 12/13 (missing ESR3 – TEVA, due to visa issues)

RESEARCHER DECLARATION (RD):

- Mandatory by the EC (Art. 19 of the GA)
- To be submitted by each beneficiary for all recruited researchers → **still missing: TEVA, TAU (Satchi-Fainaro), TU/e (Albertazzi)**

Fellow Id	First Name	Last Name	Gender
1	Rodica Alis	Olea	Female
2	Shreyas	Wagle	Male
3	Boris	Lozhkin	Male
4	Michela	Vargiu	Female
5	Africa	Galvez Flores	Female
6	Maria	Vlastara	Female
7	Melissa	van de L'Isle	Female
8	Stephen	Croke	Male
9	Linlin	Deng	Female
10	Anjana	Sathyan	Female

- Any new employment contract for the existing researcher requires a new RD.
- In case of any change (long sick leaves, maternity/parental leave, etc.) in the employment contract, the RD should be updated.

RESEARCHER DECLARATION: At the recruitment and if any change occurs

Gender Researcher

New Researcher Declaration

Researcher Information Recruitment Information Recruitment Period

+ Add Period

Recruitment Period 1

Start Date 04-10-2016

End Date 12-10-2016

Working Time Commitment Full Time

Recruitment Period 2

Start Date

End Date

Working Time Commitment

Recruitment Period 3

Start Date

End Date

Working Time Commitment

Full Time (100%)
Suspension (0%)
Part time (1 – 99%)
Maternity Leave (0%)
Paternity Leave (0%)

Delete Period

OK Cancel

PARENTAL AND MATERNITY LEAVE:

- Yes, in accordance with national legislation.
- The researcher's activity in the action is **suspended** during the maternity/parental leave.

SICK LEAVE:

- Yes, in accordance with national legislation.
- Are the costs of the leave eligible under the action?
 - For short-term leave (≤ 1 month).
 - Unit is eligible, 100%.
 - For long-term leave (> 1 month):
 - For the period that employer has to pay 100% of fellow's salary per national law → unit is eligible, 100%.
 - For the period that employer has to pay a percentage (e.g. 50%) of fellow's salary per national law → unit is eligible, 50%.
 - For the period that employer does not have to pay the fellow's salary per national law → researcher's activity in the action is **suspended**.

We will evaluate it case by case if it happens. Please contact us

RECORDS we need to prove the number of units declared:

- Evidence of open, transparent recruitment.
- Evidence of the eligibility of the fellow in terms of researcher experience, mobility and family status (e.g. CVs, copies of diplomas, ...)
- Employment contract/agreement with the fellow.
- Proof of payment of the researcher's allowances and of the deductions for social security etc.
- Evidence that the fellow was recruited and worked **full time** and exclusively on the action at the beneficiary's premises (or on secondment): this can include lab books, conference abstracts, library records, etc.
- Records and other supporting documentation on scientific and technical implementation of the action.
- **Timesheets are not an obligation for MSC Fellows** but can be used if in line with local practices.

Records must be kept for 5 years after payment of the balance (i.e. final payment)

EXAMPLES OF USEFUL DOCUMENTS: Check Recruitment Plan previously sent

ANNEX 2. Interview Assessment (Template)

Evaluator Name		Dept/Division	
Candidate name		Interview Date	

EVALUATION OF THE ACADEMIC RECORD (0-25)

Observations:	
Score	

EVALUATION OF THE EXPERIENCE (0-25)

Observations:	
Score	

EVALUATION OF THE MERITS (0-25)

Observations:	
Score	

INTERVIEW - If necessary (0-25)

Observations:	
Score	

TOTAL SCORE (0-100):

Signature _____

ANNEX 3. Minutes of the selection process (Template)

MINUTES OF THE SELECTION PROCESS FOR THE SELECTION OF ESRs

Project: THERACAT
 Beneficiary: XXX
 ESR number: ESRX
 Date: dd/mm/yyyy

Evaluators:

- YYY from XXX
- YYY from XXX
- YYY from XXX

The final prioritized ESR candidate list:

CANDIDATE	ACADEMIC	EXPERIENCE	MERITS	INTERVIEW	TOTAL

Note: Scores obtained in the selection process.

Signed by XXX	Signed by XXX	Signed by XXX
------------------	------------------	------------------

A3. FAMILY ALLOWANCE:

- Eligible for all recruited fellows who have family* at the time of recruitment.

**‘Family’ means persons linked to the researcher by marriage (or a relationship with equivalent status to a marriage recognised by the legislation of the country where this relationship was formalised) or dependent children who are actually being maintained by the researcher.*

- 500 € per month.
- **Family Allowance costs are not eligible in our project** (none of our fellows fulfills the requirement) → budget will be adjusted in future EC payments.

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

Training

TRAINING PROGRAMME:

1. Local Scientific Training activities, provided by host institutions:

- **By whom:** ESR's Supervisor/s & PhD program, and by post-doctoral staff belonging to the host research group.
- **What:** All scientific, methodological and technical aspects relevant for the individual research project of the ESR and in which the host group is expert. Participation of ESRs in local training activities should be also promoted (e.g. seminars, complementary skills sessions, etc.).

2. THERACAT Conference: Barcelona, August-September 2021

- Lectures by the different PIs, ESRs and invited external experts.
- Open also to non-member students (c.a. 50 students including THERACAT ESRs).
- Satellite of the NanoBio&Med conference in Barcelona (to be confirmed).

TRAINING PROGRAMME:

3. **Secondments** to other partner's laboratories:

- Takes place in an institution different from the host institution.
- Between members of the network with complementary expertise and nature.
- Fellows will be exposed to different disciplines and sectors (academic/industrial).
- **Secondments are MANDATORY**: Exceptions could be considered due to *force majeure* issues but PO must be informed in advance (contact IBEC as coordinator).
- **Secondment details must be uploaded at the “Funding & Tenders” Portal by each beneficiary.**
- Define the work to be performed and specific dates with the host institution in advance (**include IBEC in CC**).

4. **Network-wide** scientific/complementary skills **courses (Training Events, TE)**:

- Multidisciplinary content adapted to the different backgrounds of ESRs.
- The course organizer will be responsible to define the detailed content of the course, the schedule and the lecturers participating in it.
- Five **Training Events** (duration 4-5 days) hosted by a beneficiary.
- TE may be open to PhD students from outside the network.

TRAINING PROGRAMME:

3. **Secondments** to other partner's laboratories:

- Takes place in an institution different from the host institution.
- Between members of the network with complementary expertise and nature.
- Fellows will be exposed to different disciplines and sectors (academic/industrial).
- **Secondments are MANDATORY**: Exceptions could be considered due to *force majeure* issues but PO must be informed in advance (contact IBEC as coordinator).
- **Secondment details must be uploaded at the “Funding & Tenders” Portal by each beneficiary.**
- Define the work to be performed and specific dates with the host institution in advance (**include IBEC in CC**).

4. **Network-wide** scientific/complementary skills **courses (Training Events, TE):**

- Multidisciplinary content adapted to the different backgrounds of ESRs.
- The course organizer will be responsible to define the detailed content of the course, the schedule and the lecturers participating in it.
- Five **Training Events** (duration 4-5 days) hosted by a beneficiary.
- TE may be open to PhD students from outside the network.

SECONDMENT based individual scientific training:

- **ESR1 (GRO):** EDI – Prodrug uncaging in vitro (M12, 3 months); TEVA – Formulation (M24, 3 months).
- **ESR2 (TAU):** GRO – Metal catalyst synthesis (M12, 3 months); TAG – in vivo micelle imaging (M32, 4 months).
- **ESR3 (TEVA):** IBEC – NP imaging (M18, 4 months); TUE – SAXS characterization of NP (M30, 3 months).
- **ESR4 (TUE):** BAS – synthesis of Ru catalysts (M22, 3 months); TEVA – industrial formulation of SCPN (M30, 3 months).
- **ESR5 (EDI):** TAG – Pro-imaging PET agents (M24, 4 months); TAU – Test micelles catalysts (M34, 3 months).
- **ESR6 (TUE):** GRO – synthesis of SCPN for imaging (M24, 3 months); CRUK – training in outreach (M38, 3 months).
- **ESR7 (IBEC):** BGX – imaging of gel models (M21, 3 months); TAU – in vivo and ex vivo imaging of catalysis (M30, 4 months).
- **ESR8 (TUE):** IBEC – STORM imaging of SCPN delivery (M21, 4 months); BGX – test activity in gel cancer models (M36, 3 months).
- **ESR9 (BGX):** TUE – synthesis of gel-based catalysts (M27, 3 months); IBEC – imaging gels with STORM (M36, 4 months).
- **ESR10 (BAS):** EDI – synthesis of caged prodrugs (M27, 3 months); TEVA – encapsulate catalyst in lipid NP (M36, 3 months).
- **ESR11 (EDI):** BGX – gel-based implants (M21, 3 months); TAU – in vivo imaging (M36, 3 months).
- **ESR12 (TAG):** EDI – pro-PET agents synthesis (M18, 3 months); BAS – activable PET probe (M28, 3 months).
- **ESR13 (TAU):** IBEC – imaging of ex-vivo samples (M21, 4 months); TEVA – oral formulations (M36, 3 months).

Original plan (proposal submitted)

[illegible]

Current situation (after recruitment)

[illegible]

Original plan (proposal submitted)

[illegible]

Current situation (after recruitment)

[illegible]

TRAINING PROGRAMME:

3. Secondments to other partner's laboratories:

- Takes place in an institution different from the host institution.
- Between members of the network with complementary expertise and nature.
- Fellows will be exposed to different disciplines and sectors (academic/industrial).
- **Secondments are MANDATORY**: Exceptions could be considered due to *force majeure* issues but PO must be informed in advance (contact IBEC as coordinator).
- **Secondment details must be uploaded at the “Funding & Tenders” Portal by each beneficiary.**
- Define the work to be performed and specific dates with the host institution in advance (**include IBEC in CC**).

4. **Network-wide** scientific/complementary skills **courses (Training Events, TE):**

- Multidisciplinary content adapted to the different backgrounds of ESRs.
- The course organizer will be responsible to define the detailed content of the course, the schedule and the lecturers participating in it.
- Five **Training Events** (duration 4-5 days) hosted by a beneficiary.
- TE may be open to PhD students from outside the network.

TRAINING EVENT 2 (TE2):

- Hosted by BAS.
- Month 18: **September 23rd – 27th, 2019**
- 5 days.
- *To be attended by all ESRs and PIs involved.*

2 – Chemical synthesis & catalysis	M18, 5 days	2 ECTS	BAS
Content: This event will introduce the ESRs to the fundamental principles of designing the structure and synthesis of the prodrugs and the catalysts that will be studied throughout the project. It will also include an important chemical safety session.			
Catalysts and catalysis: from the synthetic utilization to artificial enzymes	BAS (T.Ward)	SCI	1 day
Prodrugs: design principles, synthesis and preliminary evaluation	EDI (A.Unciti-Broceta)	SCI	1½ day
Safety in chemical laboratories and research in industry and academia	TUE (A.Palmans)	LAB	1 day
How can we do better in bringing new molecules to the market: scaling up, formulations, regulations, procedures and economical aspects	TEVA (B.Avramovitch)	SCI COMP	1 day
Entrepreneurship and translation: IP and commercial exploitation	IBEC Tech Transfer	COMP	1 day

TRAINING EVENT 3 (TE3):

- Hosted by EDI.
- Month 24 (February 2020).
- 5 days.
- Coinciding with Network Meeting 2.

3 – Drug delivery & microscopy	M24, 5 days	2 ECTS	EDI
Content: This training event will focus on the design of polymeric platforms for delivering the catalysts and on in-vitro imaging, which is utilized for preliminary evaluation of the performance of the proposed therapeutic approach.			
Designing delivery systems: concepts, examples and concerns	TAU (R. Amir)	SCI	1 day
Introduction to in-vitro imaging and cell assays	EDI (A.Unciti-Broceta)	SCI	1 day
The power of microscopy techniques in biomedical research: principles and challenges	IBEC (L.Albertazzi)	SCI	1½ day
Lab tours in a microscopy facility including hands-on experience	EDI (EDI lab members)	LAB	½ day
Gender balance in academia, current situation and future perspectives	UAB (J.Gallego)	COMP	½ day
ESR Meeting 2	ESR representatives	-	½ day

TRAINING EVENT 4 (TE4):

- Hosted by TAU.
- Month 30 (August 2020).
- 5 days.

4 – Going in vivo, chemistry and cancer biology	M30, 5 days	2 ECTS	TAU
Content: This training event will give broader introduction to cancer and will focus on the different aspects of developing in vivo models and pharmacological studies for the proposed therapeutics.			
Fighting Cancer – biomedical, social and economic aspects	CRUK (F.Ratcliffe)	SCI COMP	1 day
Animal experiments – ethical and practical aspects	TAU (R.Satchi-Fainaro)	SCI LAB	1 day
Designing in vivo models and choosing the right controls	TAU (R.Satchi-Fainaro)	SCI	1 day
In Vivo imaging	TAG (M.Robillard)	SCI	1 day
How to communicate to and engage the public	CRUK (F.Ratcliffe)	COMP	½ day
ESR Meeting 3	ESR representatives	-	½ day

TRAINING EVENT 5 (TE5):

- Hosted by IBEC.
- Month 36 (February 2021).
- 7 days.
- Coinciding with Network Meeting 3.

5 – Getting ready for the next career step	M36, 7 days	3 ECTS	IBEC
Content: The last training event will be dedicated to preparing the ESRs towards completion of their studies and the development of their independent careers in industry, academia and EU agencies, including job hunting.			
Career opportunities in industry and interview simulations	Industrial PIs	COMP	1½ day
Searching for post-doc and setting the path for academic careers	Academic PIs	COMP	1 day
Innovation and Entrepreneurship including managing strategies, IPs, financing and marketing.	ESADE (J.Vinaixa)	COMP	4 day
ESR Meeting 4	ESR representatives	-	½ day

GENERAL ASPECTS:

- Each ESR will be assigned an **Assessment Commission (AC)** composed of 3 members belonging to partners other than the host partner and with different profiles (academic/non-academic).
- The ACs will meet with the ESR three times coinciding with Network Meetings 1, 2 and 3 and will have as main mission to offer a broader perspective to the training and research being carried by the ESR. It will also act as intermediate to solve conflicts or misconduct issues between the ESR and supervisor.
- ACs:
 - ESRs will send a short report describing the training received and research performed to both the AC members and to the Coordinator, including main obstacles and future plans (every 6 months). Template will be provided.
 - First assessment (1st Network Meeting): ACs will evaluate and discuss ERS's PCDP, their integration in the host institution and initial results of the research (if any).
 - Second assessment (2nd Network Meeting): the ESR will report on the evolution of its research project and of the results obtained.
 - Third assessment (3rd Network Meeting): the ESR will present the main conclusions on the work obtained so far and a draft version of the PhD thesis (preliminary).
 - Recommendations of the AC will be forwarded to the ESR and his/her supervisor (e.g. specific training events interesting for the ESR, best practices that could be implemented in the following period). Template will be provided.

ASSESSMENT COMMISSIONS COMPOSITION:

ESR / AC	<u>Assessment Commission 1</u> TAU-b (Satchi-Fainaro) GRO TEVA	<u>Assessment Commission 2</u> TUE EDI TAG	<u>Assessment Commission 3</u> BAS IBEC BGX TAU-a (Amir)
ESR1 (GRO)		X	
ESR2 (TAU-a; Amir)		X	
ESR3 (TEVA)			X
ESR4 (TUE)	X		
ESR5 (EDI)	X		
ESR6 (TUE; Albertazzi)	X		
ESR7 (IBEC)		X	
ESR8 (TUE)			X
ESR9 (BGX)		X	
ESR10 (BAS)	X		
ESR11 (EDI)			X
ESR12 (TAG)			X
ESR13 (TAU-b; Satchi-Fainaro)			X

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

Next Meetings and Events

Month	Date	Place	Duration	Meeting	Attendees
M01	May 31 st , 2018	IBEC	1 day	Kick-off Meeting	PIs
M12	March 25 – 29 th , 2019	TUE	1 day	Meeting 1	ESRs & PIs
			4 days	Training Event 1	ESRs & PIs involved
M16	June 5 th , 2019	EDI	1 day	Mid-Term Check Meeting with PO from EC	ESRs & PIs
M18	Sept. 23 – 27 th , 2019	BAS	5 days	Training Event 2	ESRs & PIs involved
M24	February 2020	EDI	1 ½ day	Meeting 2	ESRs & PIs
			5 days	Training Event 3	ESRs & PIs involved
M30	August 2020	TAU	5 days	Training Event 4	ESRs & PIs involved
M36	February 2021	IBEC	1 ½ day	Meeting 3	ESRs & PIs
			7 days	Training Event 5	ESRs & PIs involved
M42	August 2021	IBEC	1-2 days	THERACAT conference	ESRs & PIs
M48	February 2022	IBEC	1 ½ day	Final Meeting	ESRs & PIs

Month	Date	Place	Duration	Meeting	Attendees
M01	May 31 st , 2018	IBEC	1 day	Kick-off Meeting	PIs
M12	March 25 – 29 th , 2019	TUE	1 day	Meeting 1	ESRs & PIs
			4 days	Training Event 1	ESRs & PIs involved
M16	June 5 th , 2019	EDI	1 day	Mid-Term Check Meeting with PO from EC	ESRs & PIs
M18	Sept. 23 – 27 th , 2019	BAS	5 days	Training Event 2	ESRs & PIs involved
M24	February 2020	EDI	1 ½ day	Meeting 2	ESRs & PIs
			5 days	Training Event 3	ESRs & PIs involved
M30	August 2020	TAU	5 days	Training Event 4	ESRs & PIs involved
M36	February 2021	IBEC	1 ½ day	Meeting 3	ESRs & PIs
			7 days	Training Event 5	ESRs & PIs involved
M42	August 2021	IBEC	1-2 days	THERACAT conference	ESRs & PIs
M48	February 2022	IBEC	1 ½ day	Final Meeting	ESRs & PIs

MID-TERM CHECK MEETING:

- Constructive dialogue between network participants and **REA Project Officer**.
- Must be attended by: Coordinator, PIs, Representatives of Partner Organisations, ESRs.
- Agenda:
 - 1) **Introduction:** REA Project Officer and Project Coordinator (~5 min).
 - 2) **Tour de table:** presentation of research team and role within the network (all PIs).
Introduction of Partner Organisations (~30 min). **Template will be provided**
 - 3) **REA PO presentation:** monitoring of project implementation & reporting (~20 min).
 - 4) **Coordinator's report:** presentation of the Network and progress (~45-60 min).
 - 5) **Fellows' individual presentation:** presentation of every ESR, his/her background and individual research project (foreseen research, training, secondments, etc.).
Scientific results are not expected in the presentations at this stage of the project.
 - 6) **Restricted session with the fellows** (~1 to 3 hours).
 - 7) **Restricted session coordinator – Project Officer** (~15 min).
 - 8) **Feedback from PO and open discussion** (~15-30 min).
 - 9) **Site visit (optional):** Review how the host institution is operating to meeting the project objectives. **EDI?**

NETWORK MEETINGS:

- The typical duration of a Network Meeting will be **one day and a half**.
- **Progress monitoring** of the Network (short presentations by ESR fellows).
- Evaluation of scientific progress by Supervisory Board.
- **Assessment Commissions:** evaluate individual scientific and training progress of ESRs.
- Meetings will be responsibility of the host institution.
- Network Meetings will coincide with Training Events.
- Meetings shall be convened by the Coordinator with at least 45 days prior notice.
- Minutes of Meetings will be prepared by the Project Manager (15 days for approval).

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

Dissemination and Communication Actions

SCIENTIFIC PUBLICATIONS:

- Journals in the fields of chemical synthesis and catalysis, drug delivery and cancer research will be targeted as well as multidisciplinary journals.
- [Open Science](#) (Open Access journals, repositories (green way), gold way). **Each institution is responsible to publish in Open Access. Please contact us in case of any doubt.**

CONFERENCES:

Biennial International Symposium on Medicinal Chemistry (EFMC-ISMC), National Meetings organized by the ACS, international cancer meetings (e.g. AACR Annual Meetings) and drug discovery meetings (e.g. BPS, ELRIG and MlpTec meetings), NanoBioMed Conference (IBEC), international symposium on bio-orthogonal strategies (CRUK – RSC).

INSTITUTIONS WEBSITES & THERACAT WEBSITE:

Research findings will be highlighted in the consortium labs' websites (e.g. www.boomchemistry.com, <http://www.ibecbarcelona.eu>, <http://www.meijerlab.nl>), CRUK's website and THERACAT website (<https://theracat.eu/>).

SCIENTIFIC PUBLICATIONS:

- Journals in the fields of chemical synthesis and catalysis, drug delivery and cancer research will be targeted as well as multidisciplinary journals.
- [Open Science](#) (Open Access journals, repositories (green way), gold way). **Each institution is responsible to publish in Open Access. Please contact us in case of any doubt.**

CONFERENCES:

Biennial International Symposium on Medicinal Chemistry (EFMC-ISMC), National Meetings organized by the ACS, international cancer meetings (e.g. AACR Annual Meetings) and drug discovery meetings (e.g. BPS, ELRIG and MlpTec meetings), NanoBioMed Conference (IBEC), international symposium on bio-orthogonal strategies (CRUK – RSC).

INSTITUTIONS WEBSITES & THERACAT WEBSITE:

Research findings will be highlighted in the consortium labs' websites (e.g. www.boomchemistry.com, <http://www.ibecbarcelona.eu>, <http://www.meijerlab.nl>), CRUK's website and THERACAT website (<https://theracat.eu/>).

- Before dissemination, research results will be evaluated by the SB (IP & Innovation Committee) to determine its possible protectability (IPR issues) → **PROCEDURE IN CA (30 calendar days before publication).**
- Inform us of any dissemination activity performed (conference, news in websites, etc.).

THERACAT WEBPAGE: Section dedicated to the general public explaining the benefit of the results of the Network for society.

SOCIAL MEDIA: The results of THERACAT will be communicated to the public through social media such as Facebook, Twitter and LinkedIn. **THERACAT account to be created**

BLOGS: Several THERACAT institutions such as IBEC and CRUK publish divulgation blogs. These platforms will be used to disseminate the results in a simple and comprehensible way to the general public.

VIDEOS: ESRs in collaboration with TUE will prepare videos explaining for a general audience the main goals of the project, its societal implications as well as promoting the value of mobility on a personal example. **Deliverable 8.4 (month 24, Feb 2020)**

GENERAL PRESS ARTICLES: about the research being conducted and its implications will be submitted to media such as CORDIS website and related webs (News, research*eu results magazine, Horizon Magazine). **D8.5 (M30, Aug 2020) & 8.9 (M48, Feb 2022)**

SCIENCE FESTIVALS: Members of the consortium will participate to public events such as: the Edinburgh International Science Festival, the European Researchers' Night, and Night of art and Science in Groningen. **Sept 2019 European Researchers' Night (participants?)**

LOCAL MEDIA: The students will also promote their works in university newsletters, local press or radio/TV programmes to inform the general public of the discoveries and benefits related to the project proposed herein.

DISSEMINATION IS NOT COMMUNICATION

ACKNOWLEDGEMENT OF EU FUNDING:

Use EU emblem:

- High-resolution emblems are available here

<http://europa.eu/about-eu/basic-information/symbols/flag/>



Use text as indicated in GA:

This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 765497 (THERACAT).

Or equivalent paragraph

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

Deliverables and Milestones alignment

DELIVERABLES (Art. 19 of the GA):

- To be uploaded directly to the “Funding & Tenders” Portal by the Coordinator.
- All deliverables will be also uploaded on the THERACAT intranet.
- Scientific deliverables and other deliverables as defined in the GA Annex 1.
- In case of an update of a deliverable, the PO needs to be notified and re-opens the session.
- Procedure:
 - Template available on the THERACAT intranet.
 - Coordinator will inform deliverable’s leader 2 months before the deadline.
 - Reviewed by 3 other project members before submission.

MILESTONES (Art. 20.3 of the GA):

- To be reported to the PO. Status of milestones will be updated on project intranet.
- Procedure:
 - Coordinator will advise milestone’s leader 2 months before the deadline.
 - If milestone not achieved, review contingency plans & alternatives.

SCIENTIFIC & MANAGEMENT DELIVERABLES FOR THE NEXT 12 MONTHS:

#	WP	TITLE	LEADER	MONTH	STATUS	TYPE	NATURE	RTD OR MGT
D2.1	2	Network Meetings minutes (kick-off)	IBEC	1	13/08/2018	Report	Confidential	MGT
D2.2	2	Consortium Agreement	IBEC	2	28/02/2019	Report	Confidential	MGT
D2.3	2	Supervisory Board of the network	IBEC	2	14/08/2018	Other	Confidential	MGT
D8.1	8	Website completion	EDI	6	19/09/2018	Website, etc.	Public	MGT
D7.1	7	Personal Career Development Plans	IBEC	10	PENDING	Report	Confidential	MGT
D1.1	1	A - Requirement No. 1	IBEC	12	PENDING	Ethics	Confidential	RTD
D1.2	1	NEC - Requirement No. 2	IBEC	12	06/03/2019	Ethics	Confidential	RTD
D1.3	1	HCT - Requirement No. 3	IBEC	12	18/03/2019	Ethics	Confidential	RTD
D2.4	2	Network Meetings minutes (Meeting 1)	IBEC	12	PENDING	Report	Confidential	MGT
D2.5	2	Recruitment completion	TU/e	12	PENDING	Other	Confidential	MGT
D7.2	7	Training events minutes	TAU	12	PENDING	Report	Public	MGT
D7.3	7	ESRs periodic short reports and AC recommendations (M12)	IBEC	12	PENDING	Report	Confidential	MGT
D8.2	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12)	EDI	12	PENDING	Report	Confidential	MGT
D2.6	2	Progress Report	IBEC	13	PENDING	Report	Confidential	MGT
D3.1	3	Novel metal complexes for bio-orthogonal catalysis	GRO	16	PENDING	Report	Confidential	RTD
D4.1	4	Library of anticancer prodrugs	EDI	16	PENDING	Report	Confidential	RTD
D5.1	5	Library of targeted catalysts carriers	TU/e	18	PENDING	Report	Confidential	RTD
D6.1	6	Set of mCherry-labeled orthotopic models of cancer in mice	TAU	18	PENDING	Report	Confidential	RTD
D7.4	7	Training events minutes (Training event 2)	TAU	18	PENDING	Report	Public	MGT
D7.5	7	ESRs periodic short reports and AC recommendations (M18)	IBEC	18	PENDING	Report	Confidential	MGT
D6.2	6	Results of the biocompatibility tests for the catalysts	TAU	22	PENDING	Report	Confidential	RTD
D2.7	2	Network Meetings minutes (Meeting 2)	IBEC	24	PENDING	Report	Confidential	MGT
D7.6	7	Training events minutes (Training event 3)	TAU	24	PENDING	Report	Public	MGT
D7.7	7	ESRs periodic short reports and AC recommendations (M24)	IBEC	24	PENDING	Report	Confidential	MGT
D7.8	7	Updated Personal Career Development Plans (M24)	IBEC	24	PENDING	Report	Confidential	MGT
D8.3	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24)	EDI	24	PENDING	Report	Confidential	MGT
D8.4	8	THERACAT video	IBEC	24	PENDING	Website, etc.	Public	MGT

SCIENTIFIC & MANAGEMENT DELIVERABLES FOR THE NEXT 12 MONTHS: imminent submission

#	WP	TITLE	LEADER	MONTH	STATUS	TYPE	NATURE	RTD OR MGT
D2.1	2	Network Meetings minutes (kick-off)	IBEC	1	13/08/2018	Report	Confidential	MGT
D2.2	2	Consortium Agreement	IBEC	2	28/02/2019	Report	Confidential	MGT
D2.3	2	Supervisory Board of the network	IBEC	2	14/08/2018	Other	Confidential	MGT
D8.1	8	Website completion	EDI	6	19/09/2018	Website, etc.	Public	MGT
D7.1	7	Personal Career Development Plans	IBEC	10	PENDING	Report	Confidential	MGT
D1.1	1	A - Requirement No. 1	IBEC	12	PENDING	Ethics	Confidential	RTD
D1.2	1	NEC - Requirement No. 2	IBEC	12	06/03/2019	Ethics	Confidential	RTD
D1.3	1	HCT - Requirement No. 3	IBEC	12	18/03/2019	Ethics	Confidential	RTD
D2.4	2	Network Meetings minutes (Meeting 1)	IBEC	12	PENDING	Report	Confidential	MGT
D2.5	2	Recruitment completion	TU/e	12	PENDING	Other	Confidential	MGT
D7.2	7	Training events minutes	TAU	12	PENDING	Report	Public	MGT
D7.3	7	ESRs periodic short reports and AC recommendations (M12)	IBEC	12	PENDING	Report	Confidential	MGT
D8.2	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12)	EDI	12	PENDING	Report	Confidential	MGT
D2.6	2	Progress Report	IBEC	13	PENDING	Report	Confidential	MGT
D3.1	3	Novel metal complexes for bio-orthogonal catalysis	GRO	16	PENDING	Report	Confidential	RTD
D4.1	4	Library of anticancer prodrugs	EDI	16	PENDING	Report	Confidential	RTD
D5.1	5	Library of targeted catalysts carriers	TU/e	18	PENDING	Report	Confidential	RTD
D6.1	6	Set of mCherry-labeled orthotopic models of cancer in mice	TAU	18	PENDING	Report	Confidential	RTD
D7.4	7	Training events minutes (Training event 2)	TAU	18	PENDING	Report	Public	MGT
D7.5	7	ESRs periodic short reports and AC recommendations (M18)	IBEC	18	PENDING	Report	Confidential	MGT
D6.2	6	Results of the biocompatibility tests for the catalysts	TAU	22	PENDING	Report	Confidential	RTD
D2.7	2	Network Meetings minutes (Meeting 2)	IBEC	24	PENDING	Report	Confidential	MGT
D7.6	7	Training events minutes (Training event 3)	TAU	24	PENDING	Report	Public	MGT
D7.7	7	ESRs periodic short reports and AC recommendations (M24)	IBEC	24	PENDING	Report	Confidential	MGT
D7.8	7	Updated Personal Career Development Plans (M24)	IBEC	24	PENDING	Report	Confidential	MGT
D8.3	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24)	EDI	24	PENDING	Report	Confidential	MGT
D8.4	8	THERACAT video	IBEC	24	PENDING	Website, etc.	Public	MGT

SCIENTIFIC & MANAGEMENT DELIVERABLES FOR THE NEXT 12 MONTHS: M14-M18

#	WP	TITLE	LEADER	MONTH	STATUS	TYPE	NATURE	RTD OR MGT
D2.1	2	Network Meetings minutes (kick-off)	IBEC	1	13/08/2018	Report	Confidential	MGT
D2.2	2	Consortium Agreement	IBEC	2	28/02/2019	Report	Confidential	MGT
D2.3	2	Supervisory Board of the network	IBEC	2	14/08/2018	Other	Confidential	MGT
D8.1	8	Website completion	EDI	6	19/09/2018	Website, etc.	Public	MGT
D7.1	7	Personal Career Development Plans	IBEC	10	PENDING	Report	Confidential	MGT
D1.1	1	A - Requirement No. 1	IBEC	12	PENDING	Ethics	Confidential	RTD
D1.2	1	NEC - Requirement No. 2	IBEC	12	06/03/2019	Ethics	Confidential	RTD
D1.3	1	HCT - Requirement No. 3	IBEC	12	18/03/2019	Ethics	Confidential	RTD
D2.4	2	Network Meetings minutes (Meeting 1)	IBEC	12	PENDING	Report	Confidential	MGT
D2.5	2	Recruitment completion	TU/e	12	PENDING	Other	Confidential	MGT
D7.2	7	Training events minutes	TAU	12	PENDING	Report	Public	MGT
D7.3	7	ESRs periodic short reports and AC recommendations (M12)	IBEC	12	PENDING	Report	Confidential	MGT
D8.2	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12)	EDI	12	PENDING	Report	Confidential	MGT
D2.6	2	Progress Report	IBEC	13	PENDING	Report	Confidential	MGT
D3.1	3	Novel metal complexes for bio-orthogonal catalysis	GRO	16	PENDING	Report	Confidential	RTD
D4.1	4	Library of anticancer prodrugs	EDI	16	PENDING	Report	Confidential	RTD
D5.1	5	Library of targeted catalysts carriers	TU/e	18	PENDING	Report	Confidential	RTD
D6.1	6	Set of mCherry-labeled orthotopic models of cancer in mice	TAU	18	PENDING	Report	Confidential	RTD
D7.4	7	Training events minutes (Training event 2)	TAU	18	PENDING	Report	Public	MGT
D7.5	7	ESRs periodic short reports and AC recommendations (M18)	IBEC	18	PENDING	Report	Confidential	MGT
D6.2	6	Results of the biocompatibility tests for the catalysts	TAU	22	PENDING	Report	Confidential	RTD
D2.7	2	Network Meetings minutes (Meeting 2)	IBEC	24	PENDING	Report	Confidential	MGT
D7.6	7	Training events minutes (Training event 3)	TAU	24	PENDING	Report	Public	MGT
D7.7	7	ESRs periodic short reports and AC recommendations (M24)	IBEC	24	PENDING	Report	Confidential	MGT
D7.8	7	Updated Personal Career Development Plans (M24)	IBEC	24	PENDING	Report	Confidential	MGT
D8.3	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24)	EDI	24	PENDING	Report	Confidential	MGT
D8.4	8	THERACAT video	IBEC	24	PENDING	Website, etc.	Public	MGT

SCIENTIFIC & MANAGEMENT DELIVERABLES FOR THE NEXT 12 MONTHS: M19-M24

#	WP	TITLE	LEADER	MONTH	STATUS	TYPE	NATURE	RTD OR MGT
D2.1	2	Network Meetings minutes (kick-off)	IBEC	1	13/08/2018	Report	Confidential	MGT
D2.2	2	Consortium Agreement	IBEC	2	28/02/2019	Report	Confidential	MGT
D2.3	2	Supervisory Board of the network	IBEC	2	14/08/2018	Other	Confidential	MGT
D8.1	8	Website completion	EDI	6	19/09/2018	Website, etc.	Public	MGT
D7.1	7	Personal Career Development Plans	IBEC	10	PENDING	Report	Confidential	MGT
D1.1	1	A - Requirement No. 1	IBEC	12	PENDING	Ethics	Confidential	RTD
D1.2	1	NEC - Requirement No. 2	IBEC	12	06/03/2019	Ethics	Confidential	RTD
D1.3	1	HCT - Requirement No. 3	IBEC	12	18/03/2019	Ethics	Confidential	RTD
D2.4	2	Network Meetings minutes (Meeting 1)	IBEC	12	PENDING	Report	Confidential	MGT
D2.5	2	Recruitment completion	TU/e	12	PENDING	Other	Confidential	MGT
D7.2	7	Training events minutes	TAU	12	PENDING	Report	Public	MGT
D7.3	7	ESRs periodic short reports and AC recommendations (M12)	IBEC	12	PENDING	Report	Confidential	MGT
D8.2	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12)	EDI	12	PENDING	Report	Confidential	MGT
D2.6	2	Progress Report	IBEC	13	PENDING	Report	Confidential	MGT
D3.1	3	Novel metal complexes for bio-orthogonal catalysis	GRO	16	PENDING	Report	Confidential	RTD
D4.1	4	Library of anticancer prodrugs	EDI	16	PENDING	Report	Confidential	RTD
D5.1	5	Library of targeted catalysts carriers	TU/e	18	PENDING	Report	Confidential	RTD
D6.1	6	Set of mCherry-labeled orthotopic models of cancer in mice	TAU	18	PENDING	Report	Confidential	RTD
D7.4	7	Training events minutes (Training event 2)	TAU	18	PENDING	Report	Public	MGT
D7.5	7	ESRs periodic short reports and AC recommendations (M18)	IBEC	18	PENDING	Report	Confidential	MGT
D6.2	6	Results of the biocompatibility tests for the catalysts	TAU	22	PENDING	Report	Confidential	RTD
D2.7	2	Network Meetings minutes (Meeting 2)	IBEC	24	PENDING	Report	Confidential	MGT
D7.6	7	Training events minutes (Training event 3)	TAU	24	PENDING	Report	Public	MGT
D7.7	7	ESRs periodic short reports and AC recommendations (M24)	IBEC	24	PENDING	Report	Confidential	MGT
D7.8	7	Updated Personal Career Development Plans (M24)	IBEC	24	PENDING	Report	Confidential	MGT
D8.3	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24)	EDI	24	PENDING	Report	Confidential	MGT
D8.4	8	THERACAT video	IBEC	24	PENDING	Website, etc.	Public	MGT

DELIVERABLE 8.2 – Periodic Report on Dissemination & outreach (Month 12):

Please send us any dissemination/communication activity (past & future)

DELIVERABLE 2.6 – Progress Report (Month 13):

1. **General progress of the action:** information on scientific progress and trainings occurred during the period covered by this report. Describe and justify any deviation to the original Work Plan in this section.
2. **Recruitment strategy**
3. **Career development plan for each recruited researcher**
4. **Management of the action:** report on management, kick-off and management meetings, involvement of researchers, etc. Report on risks & ethics issues. Report on any difficulties, issues concerning the implementation of the Workplan due to specific rules related to the beneficiary's administration/ country legislation.
5. **Communication Activities**
6. **Impact of the Action:** describe the impact of the action on the recruited researchers and on the institutions involved or on the completion of the European Research Area.

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

Financial Reporting Information

REPORTING:

- **Progress report (Month 13):** technical report – no financial.
- **1st Periodic report (Month 24): IBEC will send a template to fill in Part A**
 - Periodic technical report (Part A by the IT system, Part B “work done” as pdf)
 - Periodic financial report (explanation of the use of resources):
 - Individual Financial Statements (IFS)
 - Periodic summary financial statement
- **2nd Periodic report and final report (Month 48):**
 - Periodic technical report
 - Periodic financial report
 - Final technical report
 - Final financial report:
 - Final summary financial statement

All the IFS and the technical reports have to be submitted electronically in one package

CONTINUOUS REPORTING to the “Funding & Tenders” Portal:

During whole project life cycle, whenever needed (Part A):

- Deliverables
- Dissemination/Communication Activities*
- Publications*
- Patents (IPR)*
- Publishable Summary (under development)
- Milestones (under development)
- Training Activities (under development)

Questionnaires:

- **Gender**
- SME impact (only for projects flagged for SME)
- Innovation (only for projects flagged for Innovation)

*Beneficiary must make it visible that the action received H2020 funding

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

Summary – To do list

ACTIONS REQUIRED (MONTH 12-24):

- **Recruitment:** (1) Researcher Declaration; (2) PCDP; (3) Strategy to deal with scientific misconduct.

Pending for TU/e (Albertazzi), TEVA, TAU (Satchi-Fainaro)

- **Secondments:** (1) agree topic and dates with receiving entity (please include us in CC); (2) upload details at “Funding & Tenders” Portal.

All PIs

- **Dissemination and outreach actions (past & future):** please send us information (papers, conference attendance/organization, news in websites, etc.).

All PIs

- **Communication activities:**

- Encourage ESRs to participate in European Researchers' Night (Sept. 2019)
- THERACAT videos (**TUE**, Deliverable 8.4, Feb 2020)

- **Assessment Commission feedback:** every 6 months.

All PIs